Comparing two weight-loss surgeries for type 2 diabetes in adults
Compares sleeve gastrectomy with bypass against sleeve gastrectomy alone in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial
Key facts
- Where
- Seongnam-si, South KoreaSee the site
- Phase
- Phase 3
Where in South Korea
- Seoul National University Bundang HospitalSeongnam-si, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Bundang Hospital
- Trial code
- NCT05211375
- Record updated
- 27 January 2022
- Original description
In this study, the effects of SG with DJB and SG alone for the treatment of type 2 diabetes mellitus (T2DM) will be compared in patients other than the two groups at both extremes who are expected to show excellent effects of metabolic surgery with SG alone (mild T2DM) and who need SG with DJB (severe T2DM).Read full original descriptionShow less
Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial
In this study, the effects of SG with DJB and SG alone for the treatment of type 2 diabetes mellitus (T2DM) will be compared in patients other than the two groups at both extremes who are expected to show excellent effects of metabolic surgery with SG alone (mild T2DM) and who need SG with DJB (severe T2DM).
This study is to target patients with poor blood sugar control despite current medical treatment, although the beta-cell function of the pancreas is preserved. Therefore, this study is aimed at patients who have been using insulin for less than 10 years with T2DM, or taking diabetic medications with HbA1c ≥ 7.0% for less than 10 years with T2DM.
The investigators hypothesize that the treatment effects of SG with DJB for T2DM will be superior to that of SG in this group
Inclusion: Age over 18 years; BMI equal to or greater than 27.5 kg/m2; T2DM duration ≤ 10 years; Using insulin, or HbA1c ≥ 7.0% while taking diabetes medication; C-peptide level higher than 1.0 ng/mL; Presence of type 2 diabetes fulfilling the following criteria; Consent to not become pregnant for at least 1 year after surgery; Willingness to provide voluntary informed consent.
Exclusion: History of previous metabolic surgery for T2DM; Treatment for alcohol and drug abuse within the last 12 months; History of gastrointestinal surgery, such as gastrectomy or anti-reflux surgery, which may affect the result of metabolic surgery; Therapy regimen of more than 3 psychiatric drugs owing to poorly controlled psychiatric disorders; Presence of uncontrolled severe gastroesophageal reflux (LA classification C or more in esophagogastroduodenoscopy); Suicidal attempts within the last 12 months; Vulnerability factors (lacking mental capacity, pregnancy or planning of pregnancy, lactation); Unsuitability as per the discretion of the researcher.